• News
  • BioTech

San Diego company reaches manufacturing deal with Swiss group

Related Special Reports

San Diego-based Femta Pharmaceuticals and the Swiss company Lonza Group Ltd. jointly announced they have reached a manufacturing agreement.

The agreement allows Femta to access Lonza’s GS Gene Expression System to help with the San Diego company’s pre-clinical rheumatoid arthritis treatment FM101.

“By leveraging Lonza’s considerable expertise in gene expression and antibody manufacturing, FM101 will have the additional benefit of speed, and yield optimization to further enhance the economies of scale for our antibody,” said Stephen Keane, president and chief operating officer of Femta Pharmaceuticals.

User Response
0 UserComments